Hot Pursuit     10-Mar-23
Marksans Pharma gets USFDA nod for Famotidine tablets
Marksans Pharma announced that it has received final approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) of Famotidine tablets, 10 mg and 20 mg, for over the counter (OTC) use.
The approved ANDA is bioequivalent to the reference listed drug (RLD), Pepcid AC tablets, a registered trademark of Johnson & Johnson Consumer Inc, which has sales of over $200 million in the US market.

OTC Famotidine tablets are acid reducers which used to treat conditions where reduction of stomach acid is needed, such as acid indigestion, occasional heartburn, or sour stomach from eating or drinking certain foods or beverages.

Mark Saldanha, managing director of Marksans Pharma, said, “We are delighted to continue OTC gastro portfolio expansion for our customers and it will help us to fulfill an important therapy gap created in Antacids market due to Ranitidine withdrawal.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company's consolidated net profit rose 31.4% to Rs 63.41 crore on 32.3% jump in net sales to Rs 479.83 crore in Q3 FY23 over Q3 FY22.

The scrip rose 0.41% to Rs 67.97 on the BSE.

Previous News
  Equity barometers hit fresh intraday low; PSU bank shares witness profit booking
 ( Market Commentary - Mid-Session 19-Apr-23   14:36 )
  Marksans Pharma fixes record date for dividend
 ( Market Beat - Reports 24-May-23   17:38 )
  Marksans Pharma to conduct board meeting
 ( Corporate News - 18-May-23   15:47 )
  Marksans Pharma consolidated net profit rises 86.01% in the March 2021 quarter
 ( Results - Announcements 31-May-21   14:16 )
  Marksans Pharma arm receives UK MHRA marketing authorization for Levetiracetam Relonchem
 ( Corporate News - 28-May-24   12:08 )
  Board of Marksans Pharma recommends final dividend
 ( Corporate News - 31-May-21   15:37 )
  Marksans Pharma revises board meeting date
 ( Corporate News - 28-Oct-21   09:30 )
  Marksans Pharma standalone net profit declines 20.73% in the December 2017 quarter
 ( Results - Announcements 12-Feb-18   17:07 )
  Marksans Pharma to convene board meeting
 ( Corporate News - 03-Nov-17   11:58 )
  Marksans Pharma drops on profit booking
 ( Hot Pursuit - 06-Apr-17   11:42 )
  Marksans Pharma reports net profit of Rs 14.40 crore in the September 2012 quarter
 ( Results - Announcements 12-Nov-12   21:42 )
Other Stories
  IndusInd Bank advances climb 16% YoY in Q1 FY25
  06-Jul-24   15:18
  Adani Wilmar reports 13% volume growth in Q1 FY25
  06-Jul-24   14:44
  Tata Motors JLR wholesale rises 5% YoY in Q1
  06-Jul-24   13:01
  Marico's domestic biz sees modest volume growth in Q1
  06-Jul-24   12:25
  Titan revenue rises 9% YoY, adds 61 stores in Q1
  06-Jul-24   11:09
  Dabur India expects mid to high digit revenue growth in Q1
  06-Jul-24   10:40
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
Back Top